Btk is required for an efficient response to erythropoietin and for SCF-controlled protection against TRAIL in erythroid progenitors.
about
Differential gene expression analysis by RNA-seq reveals the importance of actin cytoskeletal proteins in erythroleukemia cells.Neisseria gonorrhoeae kills carcinoembryonic antigen-related cellular adhesion molecule 1 (CD66a)-expressing human B cells and inhibits antibody production.TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKTIbrutinib inhibits SDF1/CXCR4 mediated migration in AMLEvidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromesTRAIL, caspases and maturation of normal and leukemic myeloid precursors.Antiproliferative and Apoptotic Effect of Curcumin and TRAIL (TNF Related Apoptosis inducing Ligand) in Chronic Myeloid Leukaemic CellsCharacteristic phenotypes associated with congenital dyserythropoietic anemia (type II) manifest at different stages of erythropoiesisPeginesatide and erythropoietin stimulate similar erythropoietin receptor-mediated signal transduction and gene induction events.Tec family kinases: regulation of FcεRI-mediated mast-cell activation.Differential regulation of Foxo3a target genes in erythropoiesis.Naturally occurring Bruton's tyrosine kinase mutations have no dominant negative effect in an X-linked agammaglobulinaemia cellular model.Phosphoprotein profiles of candidate markers for early cellular responses to low-dose γ-radiation in normal human fibroblast cells.Core erythropoietin receptor signals for late erythroblast development.The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity.Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man.The Btk-dependent PIP5K1γ lipid kinase activation by Fas counteracts FasL-induced cell death.Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer.Erythropoietin Intensifies the Proapoptotic Activity of LFM-A13 in Cells and in a Mouse Model of Colorectal Cancer.
P2860
Q32186337-B66B2F78-32BC-4076-A19A-1FC22C3D1FCEQ33883342-9A1AC755-9515-4134-A792-FF4B5E9B4438Q33916314-05015173-A67F-49CB-8CA7-35671BAC9230Q34042250-C7AEC25C-0C8F-437A-86D3-AA1535C6526AQ35083630-88A2401B-00D7-4E1E-8A30-1634AC735478Q36590964-2A389AE6-3255-4059-A44F-0F6D72173021Q36899138-98028722-F4CD-4005-999E-BFFE7A7B72AAQ37273213-F7346536-4205-4642-B7F4-32A2C1969652Q37700912-748D6495-59DF-425A-813B-204480B2DA1AQ37848482-1B71A9CC-13DA-413C-9787-CB837FAE0722Q38303809-CBDAA6BA-02B2-491E-9734-A1530F5947C2Q40017947-A8C3FE6D-3F89-4659-B0E0-7BAE67DA5DF1Q41849082-7D7C6C5F-EEB3-448E-83EA-64F4370B5682Q41996778-8AEBBDEE-8FDE-4951-A432-EA1396B56563Q44935361-55EB1FDF-DDFE-4300-B412-E1CE55D60F9AQ45870581-B89357A8-9814-4916-8302-4663C33304ADQ47298441-A9B77029-CAA4-4A66-BDAC-0060708599D3Q47379071-9BC383B4-F886-4BEE-879B-178E5FB2CEE1Q54114538-99A7AD21-A11E-470B-B40B-C926771289F2
P2860
Btk is required for an efficient response to erythropoietin and for SCF-controlled protection against TRAIL in erythroid progenitors.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Btk is required for an efficie ...... RAIL in erythroid progenitors.
@en
type
label
Btk is required for an efficie ...... RAIL in erythroid progenitors.
@en
prefLabel
Btk is required for an efficie ...... RAIL in erythroid progenitors.
@en
P2093
P2860
P356
P1476
Btk is required for an efficie ...... TRAIL in erythroid progenitors
@en
P2093
Bob Löwenberg
Emile van den Akker
Gabi Litos
Hartmut Beug
Marella de Bruijn
Marieke von Lindern
Martine Parren-van Amelsvoort
Rudi W Hendriks
Uwe Schmidt
P2860
P304
P356
10.1084/JEM.20031109
P407
P577
2004-03-08T00:00:00Z